Gordon Stein, CFO of CleanTech Lithium, explains why CTL acquired the 23 Laguna Verde licenses. Watch the video here.
Up 13%
Look at Toronto stock Pulsar since 29.2.24, from 0.55$ to 1.59$, that's 189% up! Maybe good helium news at HE1 ought to be rewarded more, similar to what's happened with plsr. Go here to see plsr's price chart and newsflow: Https://shorturl.at/lCNY6
2 red days after the MasterCard agreement
Totally bonkers.....
5% is a small rise after such a partnership. LOL.
Early days... MMs keeping the train in the station (my view) till big background buys are filled, then the rise when they're loaded up?
Tightening uranium market
Https://www.youtube.com/watch?app=desktop&v=BLcqLe55twc
when does neo start to reflect this?
This share looks oversold. Next up : 'analyse the data ... to be concluded in Q4 2023'.
I decided to sell the lot. Got burnt with IOG this Autumn, can't risk that (administration) happening again. Also this Board doesn't seem to have a clue about solving this, or - as many have suggested - want this demise to occur and then reappear in some other guise.
jason saying grow umr to 20, 30 or 40p/share. seems to me that the no. of near-production assets identified in east and south africa (by *****on & jason) are probably too numerous for maru and ska to take, as portfolio projects, and that's why imo they need a third vehicle like umr, with the advantage of a main market listing (not aim).
https://audioboom.com/posts/8416396-midweek-takeaway-with-jason-brewer-executive-director-of-unicorn-mineral-resources-lse-umr
Like many on AIM they did a (very) low-price placing. The plus side is that the funding is secure for a longer period into the future. That gives a sounder base, going forward. So let's revisit that buy territory of above 50p ;-)
Broader field mentioned: Other pre-clinical studies have been conducted that demonstrate that oral gallium maltolate may prove to be a viable treatment alternative across multiple solid tumors as well
Looks way too cheap to me. This post from the 27th is a good recap:
Agreed langland. Also, people need to be clear that RUA’s prototype heart valve is not suddenly going to be sped through trials and compete with the majors. RUA have developed a polymer/textile material that they have tested on the bench and it is standing up and exceeding minimum requirements on stress testing etc. It is comprised RUA’s Elast-Eon polymer (which already has an FDA master file for use in patients) and a medical textile. This combination was used in the vascular grafts development and found to be suitable for a heart valve leaflet.
The majors do however need a next generation material to succeed current animal gelatin based valves and if they cannot develop it themselves, they usually buyout the technology from others and that’s where RUA stand to benefit. Hence, they are hoping to strike a deal to let one major have a feel of it and test it themselves. There is a data pack and we are told it is RUA’s intention to take that to the others players too.
You can see where this might lead.